Nalo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Nalo Therapeutics Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT05514496
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇨🇳National Taiwan University Cancer Center, Taipei City, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath